Vimarsana
Biggest News Aggregation in the World

Page 3 - Dirk Arnold News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dirk Arnold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dirk Arnold Today - Breaking & Trending Today

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting - Vimarsana News

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

70% objective response rate (ORR; n=10) is nearly triple the average ORR of ~25% reported in historical control trials1-4 Data suggest pelareorep synergizes...

FinancialNewsMedia.com: Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027 - Vimarsana News

FinancialNewsMedia.com: Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027

FinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 28, 2022 /PRNewswire/ -- Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic

Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET - Vimarsana News

Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the pancreatic cancer cohort of the multi-indication phase 1/2 GOBLET...

Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027 - Vimarsana News

Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027

/PRNewswire/ -- Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors...

Oncolytics Biotech Inc.: Oncolytics Biotech Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET - Vimarsana News

Oncolytics Biotech Inc.: Oncolytics Biotech Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET

Partial responses achieved in all patients in cohort's 1b portion Expansion criteria for pancreatic cancer cohort has been met to allow for additional patient enrollment Data suggest